EUVIMEDScopri EUVIMED
Randomisierte kontrollierte Studie

Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study

Wirksamkeit und Sicherheit von Curcumin als Zusatz zu Standardchemotherapie bei Patientinnen mit fortgeschrittenem und metastasiertem Brustkrebs: randomisierte kontrollierte Studie

Shekhar Goyal, Surender K Beniwal, Pallavi Agarwal, Rajnish K Brar, Priyanka Jain, H S Kumar, Bhudev C Das iD

Phytotherapy Research · 2025-11 · 39 (11) · 5006-5024

DOI: 10.1002/ptr.70086 ↗

Auf einen Blick

Bei 120 Frauen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs war die objektive Ansprechrate unter Curcumin plus Chemotherapie höher als unter alleiniger Chemotherapie.

Fragestellung

Verbessert Curcumin als Zusatz zur Standardchemotherapie die Wirksamkeit und Sicherheit bei fortgeschrittenem/metastasiertem Brustkrebs?

Methode

Randomisierte kontrollierte Studie mit 120 Frauen; Standardchemotherapie allein oder plus orales Curcumin 1 g/Tag für 12 bis 24 Wochen. Endpunkte nach RECIST: ORR, PFS, TTP, Sicherheit.

Ergebnisse

ORR war unter Curcumin höher: 38,33 % vs. 8,33 % nach 4 Wochen post treatment (p < 0,01) und 43,40 % vs. 10,64 % nach 12 Wochen post treatment (p < 0,0031).

Schlussfolgerung der Autor:innen

Curcumin kann laut Autor:innen als sichere Zusatztherapie zu Chemotherapeutika für ein besseres Behandlungsergebnis bei Brustkrebs verwendet werden.

Kernaussagen

  • ORR höher mit Curcumin als mit Standardchemotherapie allein
  • 38,33 % vs. 8,33 % nach 4 Wochen; 43,40 % vs. 10,64 % nach 12 Wochen
  • Autor:innen berichten bessere Verträglichkeit und weniger Nebenwirkungen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in Phytotherapy Research, published online on 2025-09-03. Written by Shekhar Goyal and 6 co-authors. Institution: Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India. Major MEDLINE topics: Curcumin, Breast Neoplasms. Cited 10 times so far (Crossref); 53 references.

Auf einen BlickAbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The potential of the phytoconstituent, curcumin, as an adjuvant to chemoradiotherapy has been investigated because of its ameliorating effects, including the sensitization of cancer and cancer stem cells. Curcumin, a strong antioxidant with pharmacologically non‐toxic effects, can be used as an adjuvant with enhanced bioavailability and administered along with chemotherapy to achieve better treatment outcomes. The present study was carried out with a total of 120 women with locally advanced/metastatic breast cancer, who were randomized to receive standard chemotherapy alone or chemotherapy with oral curcumin, a 500 mg capsule (1 g/day) containing 95% curcuminoid and 1% piperine given for 12 to 24 weeks. Primary outcomes were determined using the Response Evaluation Criteria in Solid Tumors (RECIST) to determine the objective response rate (ORR), progression‐free survival (PFS), and time to tumor progression (TTP), including safety and adverse events, while the quality of life (QoL) and physical activity were secondary outcomes. ORR was significantly higher in the curcumin group than in those who received standard chemotherapy (38.33% vs. 8.33%, p < 0.01) at 4 weeks follow‐up post‐treatment, which further improved (43.40% vs. 10.64%, p < 0.0031) upon completion of 12 weeks post‐treatment. Curcumin‐treated women displayed higher physical performance, better prognosis and QoL, better tolerance to chemotherapy, fewer adverse effects, and better PFS. The study suggests that curcumin can be used as a safe adjuvant along with chemotherapeutic drugs for a better treatment outcome in breast cancer and also in other cancers.

Subjects

MeSH terms (MEDLINE)

CurcuminBreast NeoplasmsHumansFemaleMiddle AgedAdultQuality of LifeAgedChemotherapy, AdjuvantAlkaloidsNeoplasm MetastasisPiperidinesProgression-Free SurvivalBenzodioxolesTreatment OutcomePolyunsaturated Alkamides

Author keywords

TNBCadjuvant therapybreast cancerchemotherapycurcuminmetastasisrandomized controlled study

Substances

CurcuminpiperineAlkaloidsPiperidinesBenzodioxolesPolyunsaturated Alkamides

Authors and institutions

  • Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India.
  • Department of Oncology, ATRCTRI, S.P. Medical College & AG of Hospitals, Bikaner, Rajasthan, India.
  • S.P. Medical College & AG of Hospitals, Bikaner, Rajasthan, India.

ORCID profiles: Bhudev C Das

Cite

APA

Goyal, S., Beniwal, S. K., Agarwal, P., Brar, R. K., Jain, P., Kumar, H. S., & Das, B. C. (2025). Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. Phytotherapy Research, 39(11), 5006-5024. https://doi.org/10.1002/ptr.70086

Vancouver

Goyal S, Beniwal SK, Agarwal P, Brar RK, Jain P, Kumar HS, et al. Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. Phytotherapy Research. 2025;39(11):5006-5024. doi:10.1002/ptr.70086

BibTeX
@article{Goyal2025,
  author = {Goyal, Shekhar and Beniwal, Surender K and Agarwal, Pallavi and Brar, Rajnish K and Jain, Priyanka and Kumar, H S and Das, Bhudev C},
  title = {Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {11},
  pages = {5006--5024},
  doi = {10.1002/ptr.70086}
}
Start for free →